Cochlear (ASX:COH): What FY26 Implant Sales Reveal About the Nexa Rollout

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Cochlear (ASX:COH): What FY26 Implant Sales Reveal About the Nexa Rollout

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cochlear (ASX:COH) sold 56,692 cochlear implant units in FY26, up 5%.
FY26 sales Revenue was AUD 2,343.4 million, down 1% as reported.
Underlying net profit declined 22% to AUD 322.4 million.
COH shares traded at AUD 153.49 on 12 November 2026, up 1.84%.

Cochlear Limited (ASX:COH) develops and supplies implantable hearing devices, sound processors and associated hearing-care services across international markets. On 12 November 2026, its shares were trading at AUD 153.49, a rise of 1.84% for the session. Its August FY26 results detailed the rollout of the Nucleus Nexa implant platform, changes in implant pricing and a decline in underlying Earnings despite higher unit sales.

Implants, Services and Acoustics

Cochlear (ASX:COH) reports three principal product groupings: cochlear implants, Services and Acoustics. Implant systems address severe to profound hearing loss, while Services includes replacement sound processors, accessories and related products. Acoustics includes implantable bone-conduction solutions. The group serves developed and emerging healthcare markets, where reimbursement policies, referrals, clinical capacity and tender pricing affect the timing and value of sales. Implant unit growth does not necessarily move in line with reported revenue when the geographic and product mix changes.

FY26 Revenue and Profit Trends

For the year to June 2026, Cochlear (ASX:COH) reported sales revenue of AUD 2,343.4 million, down 1% on a reported basis but up 2% in constant currency. Underlying net profit fell 22% to AUD 322.4 million, while statutory net profit declined to AUD 147.3 million from AUD 388.9 million. Gross Margin decreased to 71% from 74%. The company identified sales mix, Manufacturing variances and exchange movements as factors behind the margin change.

Cochlear implant volumes increased 5% to 56,692 units, although related revenue declined 2% as reported to AUD 1,435.2 million. Services revenue increased 4% to AUD 634.9 million, while Acoustics revenue fell 1% to AUD 273.3 million. A greater mix of lower-priced emerging-market units helps explain why Volume expansion did not translate into equivalent implant revenue growth. The company reported free Cash Flow of AUD 264 million, up AUD 141 million, while net cash stood at AUD 188 million.

Nexa Launch and Market Access

The Nucleus Nexa System is a major 2026 product development for Cochlear (ASX:COH). By June, Nexa represented more than 95% of implant sales across developed markets, according to the company. An average price increase of approximately 3% was achieved, although Demand was affected by market-specific circumstances. Western European revenue declined amid surgical backlogs, industrial action and weaker conditions in some markets. The company also discussed delayed insurance approvals in the United States. Cochlear is working on referral pathways and clinician engagement as part of its longer-term hearing-treatment initiatives.

FY27 Outlook and Financial Risks

Cochlear’s August guidance called for low single-digit constant-currency revenue growth and underlying net profit of AUD 330 million to AUD 350 million in FY27. These are management expectations rather than achieved results. The company said it intended to use lower fixed costs to support approximately AUD 25 million of additional growth investment. Exchange-rate changes, tender prices, insurance decisions, treatment delays and product manufacturing expenses remain relevant uncertainties. Cochlear (ASX:COH) also continues to invest in research, including future implant technologies, which creates expenditure before associated products are commercially established.

What to Watch Next

Later disclosures may clarify developed-market implant demand, Nexa pricing, Services activity and progress with clinical referral initiatives. Monitoring gross margin and the balance between product investments and earnings will be important when assessing delivery against FY27 guidance. Reported and constant-currency growth rates should be considered separately, especially when currency movements affect the translation of overseas revenue. New clinical or regulatory developments would also need to be evaluated according to their stated status rather than assumed commercial outcomes.

Key Insights

Cochlear’s FY26 operating picture combined higher implant unit sales with reduced Underlying Profit and a lower reported gross margin. Its Nexa rollout, referral programs and cost changes are significant 2026 initiatives, while FY27 guidance remains prospective. Later results will show how product mix and access conditions develop.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.